Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Konstantinos Arnaoutakis

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Arnaoutakis, Konstantinos

Item TypeName
Grant A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients receiving Sunitinib as First-Line Therapy for Ad
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients
Grant A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Verliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Grant A randomized, open-label, Phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing subjects wi
Grant Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C
Grant A Phase 2, Randomized, Open Label Study of Figitumumab (CP-751,871) Plus Cisplatin (or Carboplatin) and Etoposide, Versus Cisplatin (or Carboplatin) a
Grant Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa
Grant An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunother
Grant Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of
Grant S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) (260760)
Grant A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Verliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Grant A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of
Grant A Phase 2, Randomized, Open Label Study of Figitumumab (CP-751,871) Plus Cisplatin (or Carboplatin) and Etoposide, Versus Cisplatin (or Carboplatin) a
Grant An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS 003) Plus Standard Treatment of Advanced Renal Cell Carcinom
Grant Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in
Grant Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C
Grant Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa
Grant S1929, Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) (273385)
Grant A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)
Grant A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)

Search Criteria
  • S Phase